Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 12/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | APEX1 | P27695 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17172448 | 0.85 | MYC (0.74) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL15714763 | 0.84 | MYC (1.00) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL15714754 | 0.81 | MYC (0.68) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL13779278 | 0.80 | MYC (1.00) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL15668582 | 0.80 | MYC (1.00) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL4375887 | 0.79 | MYC (0.65) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL2562958 | 0.78 | ALDH1A1 (0.80) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL5785631 | 0.77 | NR4A1 (0.63) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL24938792 | 0.75 | MYC (0.60) | MYCALOX15PTPN7HSD17B10ESR1 | |
| SCHEMBL30683883 | 0.75 | GAA (0.64) | MYCALOX15PTPN7HSD17B10ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| EP-2917203-B1 | METHOD FOR IDENTIFYING MYC INHIBITORS | DANA FARBER CANCER INST INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2014071247-A1 | PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | MYC 1076/4885ALOX15 1318/4885PTPN7 1828/4885 |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | MYC, MYCBP, YAP1 | MYC 1/4885ALOX15 1421/4885PTPN7 1676/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | MYC 1076/4885ALOX15 1318/4885PTPN7 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.